Japan PMDA Brief

Headline

PMDA publishes FY2026 precautions revision log covering multiple drug products across fiscal year

Executive Summary

Japan's Pharmaceuticals and Medical Devices Agency published its FY2026 running log of drug precautions revisions on October 8, 2026. The log reflects Ministry of Health, Labour and Welfare instructions issued across the fiscal year and documents revised precautions documents with supporting investigation summaries for numerous nonproprietary drug entries. The most recent entries carry an October 8, 2026 date.

Bottom Line

PMDA's FY2026 precautions revision log documents Ministry of Health, Labour and Welfare instructions to update drug labeling precautions across multiple batch dates, with the most recent entries dated October 8, 2026. The log pairs each revision with PMDA investigation summaries and, in at least one instance, a full review report. Cresthaven reading: marketing authorization holders with products appearing in this log hold revised precautions documents as the current labeling standard for those products on the Japanese market.

Key Regulatory Signals

• Ongoing Precautions Revision Cycle: PMDA's FY2026 log records precautions revisions issued by the Ministry of Health, Labour and Welfare across multiple batch dates from April 2026 through October 8, 2026. The log pairs each revision with a summary of investigation results from PMDA. Cresthaven reading: marketing authorization holders with products on the Japanese market face a recurring review cycle under which labeling precautions are updated as new safety signals emerge.
• October 8 Entries Carry No Nonproprietary Names in the Accessible Feed: The two most recent entries, both dated October 8, 2026, list revised precautions documents and investigation summaries but do not identify the nonproprietary drug names in the feed content provided. The underlying PMDA page links to the full documents for identification.
• Durvalumab Entry References a Full Review Report: The August 24, 2026 entry for durvalumab (genetical recombination) references a full review report rather than a standard summary of investigation. The source notes this document is in Japanese only.
• Investigation Appendices Flagged for Separate Access: At least one August 25, 2026 entry notes that Appendix 5 is not included in the primary file and directs readers to detailed information on revisions of precautions for the complete record. Cresthaven reading: holders relying solely on the primary precautions document for that entry may not have the complete evidentiary record without accessing the supplementary appendix.

Regulatory Delta

• PMDA's FY2026 precautions revision log continues a long-standing annual practice of publishing rolling labeling instructions from the Ministry of Health, Labour and Welfare, accompanied by supporting investigation summaries. - The October 8, 2026 batch adds two further entries, extending a revision record that began in April 2026. The feed does not identify the affected drug names. - No cross-agency coordination signal or adjacent regulatory action is evident from this release. The log reflects standard PMDA safety-labeling administration.

Materiality Classification

MEDIUM — A recurring safety-labeling administration release covering multiple drug products; marketing authorization holders with products on the Japanese market assess each revision against their current labeling to determine whether a response is warranted.

Intelligence Outlook

Monitor PMDA's FY2026 precautions revision log for additional batch entries and for identification of the nonproprietary names associated with the October 8, 2026 entries.